CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells

Abstract

The β-haemoglobinopathies, such as sickle cell disease and β-thalassaemia, are caused by mutations in the β-globin (HBB) gene and affect millions of people worldwide. Ex vivo gene correction in patient-derived haematopoietic stem cells followed by autologous transplantation could be used to cure β-haemoglobinopathies. Here we present a CRISPR/Cas9 gene-editing system that combines Cas9 ribonucleoproteins and adeno-associated viral vector delivery of a homologous donor to achieve homologous recombination at the HBB gene in haematopoietic stem cells. Notably, we devise an enrichment model to purify a population of haematopoietic stem and progenitor cells with more than 90% targeted integration. We also show efficient correction of the Glu6Val mutation responsible for sickle cell disease by using patient-derived stem and progenitor cells that, after differentiation into erythrocytes, express adult β-globin (HbA) messenger RNA, which confirms intact transcriptional regulation of edited HBB alleles. Collectively, these preclinical studies outline a CRISPR-based methodology for targeting haematopoietic stem cells by homologous recombination at the HBB locus to advance the development of next-generation therapies for β-haemoglobinopathies. These preclinical studies outline a CRISPR-based methodology for correcting β-globin gene mutations in haematopoietic stem cells to advance the development of next-generation therapies for β-haemoglobinopathies. Matthew Porteus and colleagues develop a method to improve gene editing for correction of β-haemoglobinopathies such as sickle cell disease and β-thalassaemia. By optimizing delivery and CRISPR-based homologous recombination gene correction, scaling the genome editing protocol, and including a reporter gene to enrich for edited cell populations, the authors can increase the number of corrected long-term haematopoietic stem cells ex vivo that can retain their functionality after transplantation. Initial testing suggests that this strategy could be further developed for clinical implementation.